Mammographic breast density is a recognized risk factor for breast cancer. The causes that lead to the proliferation of the glandular breast tissue and, therefore, to an increase of breast density are still unclear. However, a treatment strategy to reduce the mammary density may bring about very relevant clinical outcomes in breast cancer prevention. Myo-inositol is a six-fold alcohol of cyclohexane, has already been proved to modulate different pathways: inflammatory, metabolic, oxidative and endocrine processes, in a wide array of human diseases, including cancer and the genesis of mammary gland and breast diseases, like fibrosis, as well as metabolic and endocrine cues. Similarly, boswellic acid and betaine (three-methyl glycine) both inhibit inflammation and exert protective effects on breast physiology. Based on this scientific background, we hypothesized that a combination including, boswellic acid, betaine and myo-inositol would be able to reduce breast density working on different pathways.OBJECTIVE: Mammographic
breast density is a recognized risk factor for
breast cancer. The causes that lead to the proliferation
of the glandular breast tissue and,
therefore, to an increase of breast density are
still unclear. However, a treatment strategy to
reduce the mammary density may bring about
very relevant clinical outcomes in breast cancer
prevention.
Myo-inositol is a six-fold alcohol of cyclohexane,
has already been proved to modulate different
pathways: inflammatory, metabolic, oxidative
and endocrine processes, in a wide array of human
diseases, including cancer and the genesis
of mammary gland and breast diseases, like fibrosis,
as well as metabolic and endocrine cues.
Similarly, boswellic acid and betaine (threemethyl
glycine) both inhibit inflammation and exert
protective effects on breast physiology.
Based on this scientific background, we hypothesized
that a combinat ion including,
boswellic acid, betaine and myo-inositol would
be able to reduce breast density working on
different pathways.
PATIENTS AND METHODS: In this study,
seventy-six premenopausal women were randomly
assigned to the placebo and the experimental
drug arms (Eumastós®) for six months.
RESULTS: After 6 months of treatment, statistically
significant difference between the two
groups was recorded on the breast density reduction
(60% vs. 9%), using mammographic as
well as ultrasound examination.
CONCLUSIONS: Preliminary data collected
here with support the starting assumptions,that the association comprising boswellic acid,
betaine and myo-inositol significantly reduces
mammary density, providing the first evidence
for a new and safe approach for the management
of mammographic density treatment